Pancreatic Cancer Research

ResearcherKansai Medical UniversityNo recent work listed

Yasuo Ohashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3177-4474; OpenAlex author ID A5090955736. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
48
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper

Papers 7

  1. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (… First author DOI 10.1016/j.ejca.2018.01.081↗
  2. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patien… Co-author DOI 10.1007/s00280-017-3250-8↗
  3. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
  4. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… First author DOI 10.1136/esmoopen-2016-000151↗
  5. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Last author DOI 10.1016/s0140-6736(16)30583-9↗
  6. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Last author DOI 10.1111/cas.12674↗
  7. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Narikazu Boku · 6 shared papers, 2013–2018 · strength 0.27
  2. Shinichi Ohkawa · 5 shared papers, 2013–2017 · strength 0.22
  3. Shoji Nakamori · 4 shared papers, 2016–2018 · strength 0.21
  4. Hideki Ueno · 4 shared papers, 2013–2017 · strength 0.17
  5. Akira Fukutomi · 4 shared papers, 2013–2018 · strength 0.17
  6. Takuji Okusaka · 4 shared papers, 2013–2017 · strength 0.17
  7. Kenji Yamao · 4 shared papers, 2013–2017 · strength 0.17
  8. Yasuhiro Hagiwara · 3 shared papers, 2017–2018 · strength 0.17
  9. Taketo Yamaguchi · 3 shared papers, 2013–2017 · strength 0.13
  10. Takashi Hatori · 3 shared papers, 2013–2017 · strength 0.13
  11. Tatsuya Ioka · 3 shared papers, 2013–2017 · strength 0.13
  12. Shinichi Egawa · 3 shared papers, 2013–2017 · strength 0.13
  13. Ann‐Lii Cheng · 3 shared papers, 2013–2017 · strength 0.13
  14. Akihiro Funakoshi · 3 shared papers, 2013–2017 · strength 0.13
  15. Junji Furuse · 3 shared papers, 2013–2017 · strength 0.13
  16. Masao Tanaka · 3 shared papers, 2013–2017 · strength 0.13
  17. Takeshi Sudo · 2 shared papers, 2016–2018 · strength 0.11
  18. Yuji Kaneoka · 2 shared papers, 2016–2018 · strength 0.11
  19. Koji Imai · 2 shared papers, 2016–2018 · strength 0.11
  20. Naohiro Sata · 2 shared papers, 2016–2018 · strength 0.11
  21. Katsuhiko Uesaka · 2 shared papers, 2016–2018 · strength 0.11
  22. Yukiyasu Okamura · 2 shared papers, 2016–2018 · strength 0.11
  23. Ippei Matsumoto · 2 shared papers, 2016–2018 · strength 0.11
  24. Soichiro Morinaga · 2 shared papers, 2016–2018 · strength 0.11
  25. Satoshi Hirano · 2 shared papers, 2016–2018 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.